期刊文献+

缺氧与肿瘤化疗耐药关系研究 被引量:6

Relation of Hypoxia and drug resistance of tumor
暂未订购
导出
摘要 缺氧是晚期实体肿瘤特征性的微环境。缺氧与肿瘤的恶性进展,包括肿瘤细胞的增殖、分化、凋亡、表型的决定、血管生成、能量代谢、对治疗的抵抗)以及病人的预后密切相关。本文总结了近年来临床和实验室对肿瘤缺氧研究的相关报道,重点对肿瘤缺氧与肿瘤耐药的相关性进行归纳,为缺氧和肿瘤耐药研究做一理论铺垫,并为耐药性肿瘤的治疗提供思路。 Hypoxia is characteristic property of locally advanced solid tumors. Hypoxia is associated with development of tumor (including proliferation, differentiation, apoptosis, aggressive phenotype, angio- genesis, metabolism and resistance to treatment) and patients' prognosis. The goal of this review is to com- pile current results from experimental and clinical studies, illuslrate the interaction between hypoxia and resistance towarl oncologic treatment, so as to provide basis for further study and open the door to therapy of resistance tumor.
出处 《肿瘤药学》 CAS 2011年第5期409-414,共6页 Anti-Tumor Pharmacy
基金 教育部博士点新教师基金资助(20100162120072)
关键词 缺氧 肿瘤 耐药 Hypoxia Tumor , Drug resistance
  • 相关文献

参考文献28

  • 1孙燕.肿瘤治疗的新里程碑——靶向药物治疗[J].肿瘤药学,2011,1(1):1-5. 被引量:47
  • 2周宏灏,刘洁.抗肿瘤药物的基因导向性个体化治疗[J].肿瘤药学,2011,1(1):6-11. 被引量:40
  • 3王肇炎,王尔兵.头颈鳞癌的分子靶向药物治疗[J].肿瘤药学,2011,1(1):12-15. 被引量:2
  • 4M. J. Calzada,L. Peso.Hypoxia-inducible factors and cancer[J]. Clinical and Translational Oncology . 2007 (5)
  • 5Prof. Dr. med. Peter Vaupel,Oliver Thews,Michael Hoeckel.Treatment resistance of solid tumors[J]. Medical Oncology . 2001 (4)
  • 6Benton,R.Eppendorf Winner Evolution and Revolution inO dor Detection. Science . 2009
  • 7Schaefer,C,Okunieff,P,Vaupel,P.Oxygenation and bioen- ergetic status of murine fibrosarcomas. Oxygen transport to Tissue Xiv . 1992
  • 8Tredan,O,,Galmarini,C.M,,Patel,K,et al.Drug resistance and the solid tumor microenvironment. Journal of the Na- tional Cancer Institute . 2007
  • 9Vaupel P.Hypoxia and aggressive tumor phenotype:im-p lications for therapy and prognosis. The Oncologist . 2008
  • 10Pouyssegur,J,Dayan,F,,Mazure,N.M.Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature . 2006

二级参考文献36

  • 1孙燕.肿瘤药物治疗百年回顾与展望[J].中华肿瘤杂志,2004,26(11):701-703. 被引量:16
  • 2周爱萍,孙燕.多靶点抗肿瘤新药索拉非尼的研究进展[J].癌症进展,2006,4(6):529-533. 被引量:57
  • 3王燕,张湘茹,朱红霞,王彬,徐宁志,孙燕.吉非替尼治疗非小细胞肺癌的临床疗效预测模型的初步建立[J].中华医学杂志,2007,87(43):3069-3073. 被引量:15
  • 4Maki Ando,Yoshinori Hasegawa,Yuichi Ando.Pharmacogenetics of irinotecan: A promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecan[J]. Investigational New Drugs . 2005 (6)
  • 5Kremer JM.Methotrexate pharmacogenomios. Annals of the Rheumatic Diseases . 2006
  • 6Gurubhagavatula S,Liu G,Park S,et al.XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. Journal of Clinical Oncology . 2004
  • 7EvansWE.PharmacogeneticsofthiopurineS methyltrans feraseandthiopurinetherapy. Therapeutic Drug Monitoring . 2004
  • 8Stanulla M,Schaeffeler E,Flohr T et al.Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. The Journal of The American Medical Association . 2005
  • 9Lynch TJ,Bell DW,Sordella R,et al.Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New England Journal of Medicine, The . 2004
  • 10Mitsudomi T,Kosaka T,Endoh H,Horio Y,Hida T,Mori S,Hatooka S,Shinoda M,Takahashi T,Yatabe Y.Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. Journal of Clinical Oncology . 2005

共引文献73

同被引文献44

引证文献6

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部